Investors bought shares of Gilead Sciences Inc. (NASDAQ:GILD) on weakness during trading hours on Friday. $152.92 million flowed into the stock on the tick-up and $108.72 million flowed out of the stock on the tick-down, for a money net flow of $44.20 million into the stock. Of all stocks tracked, Gilead Sciences had the 10th highest net in-flow for the day. Gilead Sciences traded down ($0.53) for the day and closed at $76.89

A number of equities analysts recently commented on the company. Morgan Stanley restated a “hold” rating on shares of Gilead Sciences in a report on Sunday, May 29th. JPMorgan Chase & Co. reiterated a “buy” rating on shares of Gilead Sciences in a report on Saturday, May 14th. Jefferies Group reiterated a “hold” rating and set a $96.00 price target on shares of Gilead Sciences in a report on Sunday, June 12th. Piper Jaffray Cos. set a $108.00 price target on Gilead Sciences and gave the company a “buy” rating in a report on Sunday, August 21st. Finally, Argus downgraded Gilead Sciences from a “buy” rating to a “hold” rating and lowered their price target for the company from $88.00 to $81.00 in a report on Friday, July 29th. Ten research analysts have rated the stock with a hold rating, sixteen have assigned a buy rating and three have given a strong buy rating to the company. The stock presently has a consensus rating of “Buy” and a consensus price target of $106.74.

The stock has a market cap of $101.47 billion and a PE ratio of 6.75. The company’s 50 day moving average is $81.16 and its 200-day moving average is $86.85.

Gilead Sciences (NASDAQ:GILD) last posted its earnings results on Monday, July 25th. The biopharmaceutical company reported $3.08 EPS for the quarter, beating the consensus estimate of $3.02 by $0.06. The firm earned $7.78 billion during the quarter, compared to the consensus estimate of $7.80 billion. Gilead Sciences’s revenue for the quarter was down 5.7% compared to the same quarter last year. During the same quarter in the prior year, the business posted $3.15 earnings per share. On average, equities analysts expect that Gilead Sciences Inc. will post $11.77 earnings per share for the current fiscal year.

The company also recently announced a quarterly dividend, which will be paid on Thursday, September 29th. Shareholders of record on Friday, September 16th will be given a $0.47 dividend. The ex-dividend date is Wednesday, September 14th. This represents a $1.88 annualized dividend and a yield of 2.45%.

In other news, CEO John F. Milligan sold 112,000 shares of the stock in a transaction dated Monday, June 6th. The stock was sold at an average price of $86.94, for a total value of $9,737,280.00. Following the completion of the sale, the chief executive officer now owns 1,170,963 shares of the company’s stock, valued at $101,803,523.22. The sale was disclosed in a legal filing with the SEC, which is available at this link. Also, EVP Paul Rutherford Carter sold 2,000 shares of the stock in a transaction dated Monday, August 1st. The shares were sold at an average price of $79.81, for a total value of $159,620.00. Following the completion of the sale, the executive vice president now directly owns 64,122 shares of the company’s stock, valued at approximately $5,117,576.82. The disclosure for this sale can be found here.

Several large investors recently modified their holdings of GILD. TrimTabs Asset Management LLC boosted its stake in shares of Gilead Sciences by 1.9% in the fourth quarter. TrimTabs Asset Management LLC now owns 19,871 shares of the biopharmaceutical company’s stock valued at $2,011,000 after buying an additional 369 shares during the last quarter. Tredje AP fonden boosted its stake in shares of Gilead Sciences by 33.5% in the fourth quarter. Tredje AP fonden now owns 276,806 shares of the biopharmaceutical company’s stock valued at $28,010,000 after buying an additional 69,393 shares during the last quarter. Atlantic Trust Group LLC boosted its stake in shares of Gilead Sciences by 40.4% in the fourth quarter. Atlantic Trust Group LLC now owns 182,527 shares of the biopharmaceutical company’s stock valued at $18,470,000 after buying an additional 52,554 shares during the last quarter. Arrow Financial Corp boosted its stake in shares of Gilead Sciences by 12.0% in the fourth quarter. Arrow Financial Corp now owns 47,815 shares of the biopharmaceutical company’s stock valued at $4,838,000 after buying an additional 5,119 shares during the last quarter. Finally, FineMark National Bank & Trust boosted its stake in shares of Gilead Sciences by 5.8% in the fourth quarter. FineMark National Bank & Trust now owns 68,235 shares of the biopharmaceutical company’s stock valued at $6,904,000 after buying an additional 3,745 shares during the last quarter.

Gilead Sciences, Inc is a research-based biopharmaceutical company. The Company focuses on the discovery, development and commercialization of medicines in areas of unmet medical need. The Company’s principal areas of focus include human immunodeficiency virus (HIV), liver diseases, such as chronic hepatitis C virus infection and chronic hepatitis B virus infection, cardiovascular, hematology/oncology and inflammation/respiratory.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.